Is LENSAR Inc (LNSR) a Buy, Sell, or Hold?
LENSAR Inc
NASDAQ:LNSR
$5.76 USD
-$0.06 (-1.03%)
- Volume
- 32.87K
- Average Volume
- 81.74K
- Market Capitalization
- $69.72M
- P/E Ratio
- 5.88
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $13.43
- Year Low
- $5.06
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.38
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Nicholas T. Curtis |
| Industry | Medical - Equipment & Services |
| Sector | Healthcare |
| Current Symbol | LNSR |
| CUSIP | 52634L108 |
| CIK | 0001320350 |
| Web | https://www.lensar.com |
| Phone | 888 536 7271 |
| Currency | USD |
| Employees | 150 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.10 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.38 |
| Quick Ratio | 1.08 |
| Cash Ratio | 0.70 |
Sales & Book Value
| Annual Sales | $58.44M |
| Price / Sales | 1.21 |
| Cash Flow | -1.01 |
| Price / Cash Flow | -5.70 |
| Price / Book | 2.85 |
Price Target and Rating
| Average Stock Price Forecast | $10.00 |
| High Stock Price Forecast | $10.00 |
| Low Stock Price Forecast | $10.00 |
| Forecast Upside/Downside | -42.40% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.87 |
| Trailing P/E Ratio | 5.88 |
| PEG Ratio | 0.02 |
| P/E Growth | 0.02 |
| Net Income | $-34.28M |
| Net Margin | 50.94% |
| Pretax Margin | 50.94% |
| Return on Equity | -514.92% |
| Return on Assets | 44.39% |
Financials Score
| AltmanZ Score | 0.82 |
| Piotroski Score | 3.00 |
| Working Capital | 24.6M |
| Total Assets | 66.22M |
| Ebit | 29.4M |
| Market Cap | 71.27M |
| Total Liabilities | 41.65M |
Poll Results
About LENSAR Inc (NASDAQ:LNSR) Stock
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Flori ... da.
LENSAR Q1 Earnings Call Highlights
2026-05-08 16:04:15
LENSAR NASDAQ: LNSR executives told investors on Thursday that the company is moving past a “transaction-related holding pattern” after the termination of its planned merger, and is now refocusing on rebuilding commercial momentum around its ALLY femtosecond laser cataract platform. Management said first-quarter results reflected that period of uncertainty, but highlighted continued growth in recurring revenue and rising procedure volumes.
LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript
2026-05-08 11:31:25
LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript
LENSAR® Reports First Quarter 2026 Results and Provides Business Update
2026-05-08 07:00:00
7 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
2026-04-30 07:00:00
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026.
Head-To-Head Review: LENSAR (NASDAQ:LNSR) vs. Edwards Lifesciences (NYSE:EW)
2026-04-27 01:44:44
LENSAR (NASDAQ: LNSR - Get Free Report) and Edwards Lifesciences (NYSE: EW - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation. Volatility and Risk LENSAR has a beta of 0.99,
Frequently Asked Questions
-
What is the current LENSAR Inc (LNSR) stock price?
-
LENSAR Inc(NASDAQ:LNSR) stock price is $5.76 in the last trading session. During the trading session, LNSR stock reached the peak price of $13.425 while $5.06 was the lowest point it dropped to. The percentage change in LNSR stock occurred in the recent session was --1.03% while the dollar amount for the price change in LNSR stock was -$-0.06.
-
LNSR's industry and sector of operation?
-
The NASDAQ listed LNSR is part of Medical - Equipment & Services industry that operates in the broader Healthcare sector.
-
Who are the executives of LNSR?
-
Michael A. Rossi | Interim CFO & Principal Financial Officer and Secretary
Alan Connaughton | Chief Operating Officer
Kendra W. Wong | Principal Accounting Officer
Nicholas T. Curtis | President, Chief Executive Officer & Director
| -
How many employees does LNSR have?
-
Number of LNSR employees currently stands at 150. LNSR operates from 2800 Discovery Drive, Orlando, FL 32826, US.
-
Link for LNSR official website?
-
Official Website of LNSR is: https://www.lensar.com
-
How do I contact LNSR?
-
LNSR could be contacted at phone #888 536 7271 and can also be accessed through its website. LNSR operates from 2800 Discovery Drive, Orlando, FL 32826, US.
-
How many shares of LNSR are traded daily?
-
The average number of LNSR shares traded daily for last 3 months was 81.74K.
-
What is the market cap of LNSR currently?
-
The market value of LNSR currently stands at $69.72M with its latest stock price at $5.76